![Medication research visual for Zepbound Side Effects: Complete Guide with Frequency Data [2026]](/_next/image?url=%2Fimages%2Fcompounds%2Fretatrutide-hero.webp&w=1920&q=75&dpl=dpl_JA2MP2HEHCn44PEGr4Ej5L1nGjkx "Zepbound Side Effects: Complete Guide with Frequency Data [2026] visual guide")
TL;DR
Zepbound (tirzepatide) causes GI side effects in most patients. In the SURMOUNT-1 trial (NCT04184622), nausea affected 29% of patients on the 15mg dose compared to 9% on placebo. Most side effects are mild, peak during dose escalation, and ease within 4 to 8 weeks.
Serious events like pancreatitis occur in fewer than 1% of patients.
Zepbound is the brand name for tirzepatide approved specifically for chronic weight management. The FDA granted approval in November 2023 based on the SURMOUNT clinical trial program, which enrolled over 5,000 participants. Understanding the side effect profile is important before starting treatment, and this guide breaks down every documented adverse event with real frequency numbers from the clinical data.
All data here comes from the SURMOUNT-1 trial (NCT04184622) and the Zepbound prescribing information, unless otherwise noted. We cite specific percentages so you can have an informed conversation with your prescriber about what to expect.
What Are the Most Common Zepbound Side Effects?
The most common Zepbound side effects are gastrointestinal. In the SURMOUNT-1 trial (NCT04184622), nausea affected 24% to 29% of participants depending on dose, compared to just 9% on placebo. These GI symptoms are driven by tirzepatide's dual GIP/GLP-1 mechanism, which slows gastric emptying and changes how your digestive system processes food.
Most patients describe these side effects as mild to moderate. They tend to show up in the first 2 to 4 weeks after starting a new dose and then gradually fade. Here is a complete breakdown by dose level from the SURMOUNT-1 trial[1].
| Side Effect | 5mg | 10mg | 15mg | Placebo | Typical Onset | Typical Resolution |
|---|---|---|---|---|---|---|
| Nausea | 24% | 27% | 29% | 9% | Week 1 to 2 after dose change | 4 to 8 weeks |
| Diarrhea | 15% | 17% | 21% | 7% | Week 1 to 3 | 2 to 6 weeks |
| Constipation | 9% | 11% | 11% | 5% | Week 2 to 4 | Ongoing for some |
| Vomiting | 6% | 10% | 13% | 2% | Week 1 to 2 after dose change | 2 to 4 weeks |
| Injection site reactions | 3% | 5% | 7% | 1% | Within hours of injection | 1 to 3 days |
| Abdominal pain | 5% | 6% | 7% | 4% | Variable | 2 to 4 weeks |
| Dyspepsia | 5% | 6% | 7% | 3% | After meals | 4 to 6 weeks |
| Fatigue | 3% | 4% | 5% | 2% | Week 1 to 2 | 4 to 6 weeks |
| Hair loss | 3% | 4% | 6% | 1% | Month 3 to 6 | Stabilizes by month 9 to 12 |
A few patterns stand out. Nausea and vomiting are dose-dependent, meaning they get more frequent as the dose goes up. Constipation, however, plateaus at 11% for both the 10mg and 15mg doses.
Hair loss is likely related to rapid weight loss rather than the medication itself, since it typically begins months after treatment starts.
What Are the Serious Side Effects and Warning Signs?
Serious side effects from Zepbound are uncommon but important to recognize. The SURMOUNT-1 trial (NCT04184622) documented pancreatitis in fewer than 1% of participants, and gallbladder events occurred in roughly 1.5% of the tirzepatide group compared to 0.8% on placebo. Zepbound also carries a boxed warning about thyroid C-cell tumors, though this has only been observed in rodent studies and not confirmed in humans.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
For a complete cost breakdown, see our compare tirzepatide pharmacies.
These serious events require immediate medical attention if they occur. Knowing the warning signs can help you act quickly.
Pancreatitis (fewer than 1%)
Acute pancreatitis is a rare but potentially dangerous inflammation of the pancreas. In the SURMOUNT trials, it occurred in fewer than 1% of tirzepatide-treated patients. Symptoms include severe, persistent upper abdominal pain that often radiates to the back, along with nausea and vomiting that doesn't improve.
If you experience sudden, intense stomach pain that doesn't go away, stop taking Zepbound and contact your healthcare provider or go to the emergency room immediately.
Gallbladder Events (~1.5%)
Gallbladder problems including gallstones and cholecystitis were reported in approximately 1.5% of SURMOUNT-1 participants on tirzepatide. Rapid weight loss itself increases the risk of gallstones, so this is partly a consequence of effective treatment. Watch for sharp pain in the upper right abdomen, especially after eating fatty meals, along with fever or yellowing of the skin.
Thyroid C-Cell Tumors (Boxed Warning)
Zepbound carries an FDA boxed warning about the risk of thyroid C-cell tumors. This warning is based on animal studies where tirzepatide caused thyroid tumors in rats at clinically relevant doses. No cases have been confirmed in humans.
But Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Tell your doctor if you notice a lump or swelling in your neck, difficulty swallowing, hoarseness, or shortness of breath.
Other Serious but Rare Events
Severe allergic reactions (anaphylaxis) have been reported in rare cases. Symptoms include swelling of the face, lips, tongue, or throat, difficulty breathing, rapid heartbeat, and severe rash. Kidney injury has also been reported, usually in the context of dehydration from severe vomiting or diarrhea.
Patients with existing kidney disease should be monitored closely.
How Can You Manage Zepbound Side Effects?
Managing Zepbound side effects effectively comes down to a few practical strategies that most healthcare providers recommend. According to SURMOUNT trial protocols and clinical guidance, the slow dose-escalation schedule is the single most important tool for minimizing GI symptoms. Patients who follow the recommended 4-week intervals between dose increases report significantly fewer problems than those who escalate faster.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Managing Nausea
Eat smaller, more frequent meals throughout the day instead of 2 or 3 large ones. Bland, low-fat foods are easier on your stomach during the adjustment period. Avoid lying down immediately after eating, and stay well hydrated with small sips of water throughout the day.
Ginger tea, peppermint, and over-the-counter remedies like Pepto-Bismol may provide additional relief. If nausea is severe, your provider can prescribe ondansetron (Zofran) to use during the first weeks of a new dose. Timing your injection in the evening before bed can also help, since you sleep through the peak nausea window.
Managing Constipation
Increase your fiber intake gradually with vegetables, fruits, and whole grains. Aim for at least 64 ounces of water daily, since the slowed gastric emptying can dehydrate stool. Regular physical activity, even a 20-minute walk after meals, stimulates bowel motility.
If dietary changes aren't enough, a fiber supplement like psyllium husk or an osmotic laxative like MiraLAX can help. Avoid stimulant laxatives for daily use. Talk to your provider if constipation persists beyond 3 to 4 weeks.
Managing Diarrhea
Stay hydrated with electrolyte-containing fluids. Avoid high-fat, greasy, and spicy foods, which can worsen loose stools. The BRAT diet (bananas, rice, applesauce, toast) can help during acute episodes.
If diarrhea is persistent, your provider may recommend loperamide (Imodium) for short-term relief.
Managing Injection Site Reactions
Rotate your injection sites between the abdomen, thigh, and upper arm. Let the pen warm to room temperature for 15 to 30 minutes before injecting. Clean the area with an alcohol swab and let it dry completely.
If redness or itching occurs, a cold compress for 10 minutes after injection can reduce inflammation.
How Do Zepbound Side Effects Change by Dosage?
Side effects generally increase as the Zepbound dose goes up, according to SURMOUNT-1 (NCT04184622) data. Nausea jumps from 24% at 5mg to 29% at 15mg, while vomiting more than doubles from 6% to 13% across the same range. The dose-escalation schedule exists specifically to give your body time to adjust at each level before moving higher.
The standard Zepbound titration starts at 2.5mg weekly for 4 weeks, then increases to 5mg. From there, your provider may increase to 7.5mg, 10mg, 12.5mg, and ultimately 15mg, with at least 4 weeks at each dose. Many patients find a dose where they get good results with manageable side effects and stay there rather than escalating to the maximum.
| Dose Level | Duration | Expected GI Side Effects | Clinical Notes |
|---|---|---|---|
| 2.5mg (starting) | 4 weeks minimum | Mild nausea in some patients | Not a therapeutic dose, used only for titration |
| 5mg | 4+ weeks | Nausea 24%, diarrhea 15%, vomiting 6% | First therapeutic dose, some patients stay here |
| 7.5mg | 4+ weeks | Moderate increase from 5mg levels | Intermediate step, data extrapolated between 5mg and 10mg |
| 10mg | 4+ weeks | Nausea 27%, diarrhea 17%, vomiting 10% | Good balance of efficacy and tolerability for many |
| 12.5mg | 4+ weeks | Moderate increase from 10mg levels | Intermediate step before maximum dose |
| 15mg (maximum) | Maintenance | Nausea 29%, diarrhea 21%, vomiting 13% | Maximum weight loss (~22.5% in SURMOUNT-1) but highest side effect burden |
If side effects become intolerable at a new dose, your provider may reduce you back to the previous level for an additional 4 weeks before trying again. This approach works well for most patients and doesn't compromise long-term results.
Zepbound Side Effects vs Wegovy Side Effects: How Do They Compare?
Zepbound (tirzepatide) and Wegovy (semaglutide) are the two leading FDA-approved weight loss injections, and their side effect profiles differ meaningfully. In head-to-head comparisons using data from SURMOUNT-1 (NCT04184622) and STEP-1[2] (NCT03548935), Wegovy causes higher rates of nausea (44% vs 29%), vomiting (24% vs 13%), and diarrhea (30% vs 21%) at their respective maximum doses.
The difference likely comes from their mechanisms of action. Zepbound activates both GIP and GLP-1 receptors, while Wegovy activates only GLP-1. Some researchers believe the GIP component moderates GI side effects, though both medications still cause significant digestive symptoms.
| Side Effect | Zepbound 15mg (SURMOUNT-1) | Wegovy 2.4mg (STEP-1) | Difference |
|---|---|---|---|
| Nausea | 29% | 44% | Wegovy 15 percentage points higher |
| Diarrhea | 21% | 30% | Wegovy 9 percentage points higher |
| Vomiting | 13% | 24% | Wegovy 11 percentage points higher |
| Constipation | 11% | 24% | Wegovy 13 percentage points higher |
| Headache | ~5% | 14% | Wegovy notably higher |
| GI discontinuation rate | ~4.3% | ~7% | Wegovy nearly double |
| Gallbladder events | ~1.5% | ~2.6% | Wegovy modestly higher |
| Pancreatitis | <1% | <1% | Similar |
One important caveat: these numbers come from separate trials with different patient populations, so direct comparison has limitations. But the consistent pattern of lower GI side effects with tirzepatide has been noted across multiple analyses. For patients who are particularly sensitive to nausea, Zepbound may be the more tolerable option.
For a full breakdown of Wegovy's side effect profile, see our Wegovy side effects guide.
Who Should Not Take Zepbound?
Zepbound is contraindicated in several patient groups based on the FDA prescribing information and SURMOUNT trial exclusion criteria. Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 shouldn't use Zepbound due to the thyroid C-cell tumor risk observed in animal studies. The medication is also not recommended during pregnancy or while breastfeeding.
Patients with a history of pancreatitis should discuss the risks carefully with their provider. Severe gastrointestinal disease, including gastroparesis, may make GI side effects significantly worse. Zepbound hasn't been studied in combination with other GLP-1 receptor agonists and shouldn't be used alongside insulin for weight loss purposes unless specifically directed by an endocrinologist.
People with type 1 diabetes shouldn't use Zepbound. If you have type 2 diabetes and take insulin or sulfonylureas, your provider will likely adjust those medications to reduce the risk of hypoglycemia when starting Zepbound.
Frequently Asked Questions About Zepbound Side Effects
How long do Zepbound side effects last?
Most GI side effects like nausea and diarrhea peak in the first 1 to 2 weeks after starting a new dose and resolve within 4 to 8 weeks. In the SURMOUNT-1 trial (NCT04184622), the majority of reported GI events were classified as mild to moderate and transient. Some patients experience brief flare-ups each time the dose increases, but these episodes typically become less intense over time.
Does Zepbound cause hair loss?
Hair loss (alopecia) was reported in 3% to 6% of SURMOUNT-1 participants on tirzepatide. This is most likely related to rapid weight loss rather than a direct drug effect, as any significant caloric deficit can trigger telogen effluvium, a temporary form of diffuse hair shedding. Hair typically stabilizes 9 to 12 months after weight loss plateaus.
Can Zepbound cause pancreatitis?
Acute pancreatitis occurred in fewer than 1% of participants in the SURMOUNT clinical trials. While rare, it's a recognized risk. Symptoms include severe, persistent abdominal pain radiating to the back, nausea, and vomiting.
If you suspect pancreatitis, stop Zepbound and seek emergency care immediately.
Is nausea from Zepbound worse than from Wegovy?
No. Clinical trial data suggests Zepbound causes less nausea than Wegovy. SURMOUNT-1 reported nausea in 29% of patients at the highest Zepbound dose, while STEP-1 reported nausea in 44% of patients on Wegovy 2.4mg.
These are separate trials, so direct comparison has limits, but the pattern is consistent across multiple studies.
What should I eat while taking Zepbound to reduce side effects?
Focus on small, frequent meals built around lean protein, cooked vegetables, and complex carbohydrates. Avoid large, high-fat meals, fried foods, and carbonated drinks, especially in the first few weeks of a new dose. Many patients find that bland foods like rice, chicken breast, bananas, and toast are easiest to tolerate during the adjustment period.
Can I drink alcohol while taking Zepbound?
There's no absolute contraindication, but alcohol can worsen nausea, dehydration, and GI symptoms. Zepbound slows gastric emptying, which can change how quickly alcohol is absorbed and may intensify its effects. Most providers recommend limiting alcohol, especially during dose escalation.
Does Zepbound affect your mood or mental health?
The SURMOUNT trials did not identify a statistically significant increase in depression or suicidal ideation with tirzepatide. But the FDA requires monitoring for mood changes with all GLP-1 receptor agonists as a precautionary measure. If you notice persistent changes in mood, increased anxiety, or thoughts of self-harm, contact your healthcare provider immediately.
When should I call my doctor about Zepbound side effects?
Call your doctor if you experience severe abdominal pain that doesn't resolve, persistent vomiting that prevents you from keeping fluids down, signs of an allergic reaction (swelling of face, lips, or throat), vision changes, or symptoms of kidney problems like decreased urination or swelling in your legs. These may indicate a serious adverse event that requires medical evaluation.
Related Resources
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]